Drug Trial Radar · NCT06604949
A Study of Single Dose of LP-003 in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Actual
Start
Oct 23, 2024
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Longbio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Sep 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy subjects.
Conditions
- Chronic Spontaneous Urticaria
Interventions
LP-003 200mgDrug
Subcutaneous injection of 200 mg LP-003
PlaceboDrug
Subcutaneous injection of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AE)Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai General Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.